1. Home
  2. BAFN vs CELU Comparison

BAFN vs CELU Comparison

Compare BAFN & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BAFN
  • CELU
  • Stock Information
  • Founded
  • BAFN 1999
  • CELU 2016
  • Country
  • BAFN United States
  • CELU United States
  • Employees
  • BAFN N/A
  • CELU N/A
  • Industry
  • BAFN Savings Institutions
  • CELU Biotechnology: Pharmaceutical Preparations
  • Sector
  • BAFN Finance
  • CELU Health Care
  • Exchange
  • BAFN Nasdaq
  • CELU Nasdaq
  • Market Cap
  • BAFN 63.2M
  • CELU 64.3M
  • IPO Year
  • BAFN N/A
  • CELU N/A
  • Fundamental
  • Price
  • BAFN $8.51
  • CELU $2.10
  • Analyst Decision
  • BAFN
  • CELU Strong Buy
  • Analyst Count
  • BAFN 0
  • CELU 1
  • Target Price
  • BAFN N/A
  • CELU $6.00
  • AVG Volume (30 Days)
  • BAFN 21.9K
  • CELU 135.6K
  • Earning Date
  • BAFN 10-23-2025
  • CELU 08-29-2025
  • Dividend Yield
  • BAFN 3.79%
  • CELU N/A
  • EPS Growth
  • BAFN 100.65
  • CELU N/A
  • EPS
  • BAFN 1.89
  • CELU N/A
  • Revenue
  • BAFN $78,211,000.00
  • CELU $44,590,000.00
  • Revenue This Year
  • BAFN N/A
  • CELU $23.29
  • Revenue Next Year
  • BAFN N/A
  • CELU N/A
  • P/E Ratio
  • BAFN $4.48
  • CELU N/A
  • Revenue Growth
  • BAFN 0.67
  • CELU 4.45
  • 52 Week Low
  • BAFN $6.40
  • CELU $1.00
  • 52 Week High
  • BAFN $19.75
  • CELU $5.22
  • Technical
  • Relative Strength Index (RSI)
  • BAFN 38.42
  • CELU 45.29
  • Support Level
  • BAFN $8.40
  • CELU N/A
  • Resistance Level
  • BAFN $8.77
  • CELU $2.53
  • Average True Range (ATR)
  • BAFN 0.33
  • CELU 0.28
  • MACD
  • BAFN 0.15
  • CELU -0.20
  • Stochastic Oscillator
  • BAFN 12.70
  • CELU 52.37

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: